(AOF) – Crossject, which will soon develop and market a portfolio of combination drugs dedicated to emergency situations, has signed a commercial agreement with Eton covering the United States and Canada. Eton specializes in the development and commercialization of innovative pharmaceutical products in endocrinology. The French medtech will receive five million dollars before the commercialization of Zeneo Hydrocortisone.
In the commercial phase, Crossject will receive a sale price for each product supplied, and royalties of 10% on Eton’s net sales, as well as up to $ 6 million upon reaching 3 commercial milestones.
AOF – LEARN MORE
Excellent prospects for the sector
According to Moody’s, the turnover of the sector should increase by 4 to 6% in 2021, against 2 to 4% initially forecast.
The top five vaccine manufacturers (Pfizer-BioNTech, Moderna, AstraZeneca, Novavax and Johnson & Johnson) should benefit greatly from this growth, even if there are uncertainties about production capacities. Treatment manufacturers (Gilead, Eli Lilly and Regeneron in particular) should not be left out.
Alongside the opportunities there are also threats, one of which is potential price reductions, in particular in the United States, the world’s largest market. The rise of biosimilars (generics of biological drugs) should also help pull prices down.
– .
